{
    "nctId": "NCT03096613",
    "officialTitle": "Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial",
    "inclusionCriteria": "* Aged 18 years or older, male or female.\n* Systolic heart failure with New York Heart Association (NYHA) class II-III.\n* Left ventricular ejection fraction (LVEF) less than 40% by echocardiography during screening and randomization.\n* SCH (TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference range).\n* Having received standard HF therapy for at least 2 weeks, having reached target dose or max tolerable dose.\n* Provided informed consent.\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Acute heart failure or acute exacerbation of chronic heart failure within the past 2 weeks.\n* Scheduled cardiac resynchronization therapy or heart transplantation.\n* History of malignant tumor or life expectancy under 12 months.\n* Already on medications that may affect thyroid function (L-T4, carbimazole, propylthiouracil, amiodarone, lithium).\n* Pregnancy and lactation period.\n* Participation in another clinical trial within the past 30 days.\n* Contraindication or intolerance to evidence-based therapy for CHF, such as beta-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.\n* Known hypersensitivity to the trial treatment(s) or diluents (when applicable), including placebo or other comparator drug(s).\n* Untreated adrenal insufficiency.\n* Untreated pituitary insufficiency.\n* Untreated thyrotoxicosis.\n* Treatment with levothyroxine must not be initiated in patients with acute myocardial infarction, acute myocarditis, or acute pancarditis.\n* Severe renal dysfunction (eGFR\u226430 ml/min/1.73m2).\n* Significant hepatic impairment (Serum GPT \\> 120 U/L).\n* Any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol."
}